[1] |
Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer's disease[J].Alzheimers Dement, 2007, 3(3): 186-191.
|
[2] |
Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease[J]. N Engl J Med, 2003, 348(14): 1356-1364.
|
[3] |
Alzheimer's Association. 2012 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2012, 8(2): 131-168.
|
[4] |
Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study[J]. Lancet, 2005, 366(9503): 2112-2117.
|
[5] |
Campos C, Rocha NB, Vieira RT, et al. Treatment of cognitive deficits in Alzheimer's disease: a psychopharmacological review[J]. Psychiatr Danub, 2016, 28(1): 2-12.
|
[6] |
Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions[J]. Lancet Neurol, 2015, 14(9): 926-944.
|
[7] |
Kang JH, Korecka M, Figurski MJ, et al. The Alzheimer's disease neuroimaging initiative 2 biomarker core: a review of progress and plans[J]. Alzheimers Dement, 2015, 11(7): 772-791.
|
[8] |
Yang JS, Lai EC. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants[J]. Mol Cell, 2011, 43(6): 892-903.
|
[9] |
Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and function[J]. Thromb Haemost, 2012, 107(4): 605-610.
|
[10] |
Del VV, Denti MA. MicroRNA and lung cancer[J]. Adv Exp Med Biol, 2015, 889: 153-177.
|
[11] |
Samanta S, Balasubramanian S, Rajasingh S, et al. MicroRNA: a new therapeutic strategy for cardiovascular diseases[J]. Trends Cardiovasc Med, 2016, pii: S1050-1738(16)00048-7[Epub ahead of print].
|
[12] |
Hill JM, Lukiw WJ. microRNA (miRNA)-mediated pathogenetic signaling in Alzheimer's disease (AD) [J]. Neurochem Res, 2016, 41(1-2): 96-100.
|
[13] |
Ambros V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006): 350-355.
|
[14] |
Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
|
[15] |
Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels[J]. Nature, 2010, 466(7308): 835-840.
|
[16] |
Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions[J]. Mol Cell Pharmacol, 2011, 3(3): 83-92.
|
[17] |
Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways[J]. J Alzheimers Dis, 2008, 14(1): 27-41.
|
[18] |
Garza-Manero S, Arias C, Bermudez-Rattoni F, et al. Identification of age-and disease-related alterations in circulating miRNAs in a mouse model of Alzheimer's disease[J]. Front Cell Neurosci, 2015, 9: 53.
|
[19] |
Luo H, Wu Q, Ye X, et al. Genome-wide analysis of miRNA signature in the APPswe/PS1DeltaE9 mouse model of alzheimer's disease[J]. PLoS One, 2014, 9(8): e101725.
|
[20] |
Liu QY, Chang MN, Lei JX, et al. Identification of microRNAs involved in Alzheimer's progression using a rabbit model of the disease[J]. Am J Neurodegener Dis, 2014, 3(1): 33-44.
|
[21] |
van Harten AC, Mulders J, Scheltens P, et al. Differential expression of microRNA in cerebrospinal fluid as a potential novel biomarker for Alzheimer's disease[J]. J Alzheimers Dis, 2015, 47(1): 243-252.
|
[22] |
Denk J, Boelmans K, Siegismund C, et al. MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer's disease[J]. PLoS One, 2015, 10(5): e0126423.
|
[23] |
Muller M, Jakel L, Bruinsma IB, et al. MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid[J]. Mol Neurobiol, 2015[Epub ahead of print].
|
[24] |
Tan L, Yu JT, Liu QY, et al. Circulating miR-125b as a biomarker of Alzheimer's disease[J]. J Neurol Sci, 2014, 336(1-2): 52-56.
|
[25] |
Galimberti D, Villa C, Fenoglio C, et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease[J]. J Alzheimers Dis, 2014, 42(4): 1261-1267.
|
[26] |
Tan L, Yu JT, Tan MS, et al. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease[J]. J Alzheimers Dis, 2014, 40(4): 1017-1027.
|
[27] |
Sorensen SS, Nygaard AB, Christensen T. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia——an exploratory study[J]. Transl Neurodegener, 2015[Epub ahead of print].
|
[28] |
Bhatnagar S, Chertkow H, Schipper HM, et al. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci, 2014, 7: 2.
|
[29] |
Liu CG, Wang JL, Li L, Wang PC. MicroRNA-384 regulates both amyloid precursor protein and beta-secretase expression and is a potential biomarker for Alzheimer's disease[J]. Int J Mol Med, 2014, 34(1): 160-166.
|
[30] |
Lugli G, Cohen AM, Bennett DA, et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer disease: altered expression and prospects for biomarkers[J]. PLoS One, 2015, 10(10): e0139233.
|
[31] |
Ren RJ, Zhang YF, Dammer EB, et al. Peripheral blood microrna expression profiles in Alzheimer's disease: screening, validation, association with clinical phenotype and implications for molecular mechanism[J]. Mol Neurobiol, 2015.[Epub ahead of print]
|
[32] |
Zhu Y, Li C, Sun A, et al. Quantification of microRNA-210 in the cerebrospinal fluid and serum: implications for Alzheimer's disease[J]. Exp Ther Med, 2015, 9(3): 1013-1017.
|
[33] |
Jia LH, Liu YN. Downregulated serum miR-223 servers as biomarker in Alzheimer's disease[J]. Cell Biochem Funct, 2016.[Epub ahead of print]
|
[34] |
Dong H, Li J, Huang L, et al. Serum microRNA profiles serve as novel viomarkers for the diagnosis of Alzheimer's disease[J]. Dis Markers, 2015, 2015: 625659.
|
[35] |
Geekiyanage H, Jicha GA, Nelson PT, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease[J]. Exp Neurol, 2012, 235(2): 491-496.
|
[36] |
Satoh J, Kino Y, Niida S. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer's disease from public data[J]. Biomark Insights, 2015, 10: 21-31.
|
[37] |
Wu HZ, Ong KL, Seeher K, et al. Circulating microRNAs as biomarkers of Alzheimer's disease: a systematic review[J]. J Alzheimers Dis, 2015, 49(3): 755-766.
|
[38] |
Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment[J]. Mol Psychiatry, 2015, 20(10): 1188-1196.
|
[39] |
Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology[J]. PLoS One, 2014, 9(5): e94839.
|
[40] |
Pereira PA, Tomas JF, Queiroz JA, et al. Recombinant pre-miR-29b for Alzheimer s disease therapeutics[J]. Sci Rep, 2016, 6: 19946.
|
[41] |
Liu Z, Wang C, Wang X, et al. Therapeutic effects of transplantation of as-mir-937-expressing mesenchymal stem cells in murine model of Alzheimer's disease[J]. Cell Physiol Biochem, 2015, 37(1): 321-330.
|
[42] |
Song J, Lee JE. miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function[J]. Front Aging Neurosci, 2015, 7: 61.
|